IgA Nephropathy Secondary to Ipilimumab Use

Ipilimumab is a human monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 approved for the treatment of non-small-cell lung cancer (NSCLC) and other malignancies. Despite a high prevalence of other immune-related adverse events (irAEs), checkpoint inhibitor (CPI)-related nephro...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sean C. Dougherty, Nisa Desai, Helen P. Cathro, Amanda Renaghan
Formato:	article
Lenguaje:	EN
Publicado:	Karger Publishers 2021
Materias:	acute renal failure histopathology iga nephropathy kidney biopsy proteinuria Diseases of the genitourinary system. Urology RC870-923
Acceso en línea:	https://doaj.org/article/c509c83f285d4cb4aa1d2601709d1b42
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c509c83f285d4cb4aa1d2601709d1b42
record_format	dspace
spelling	oai:doaj.org-article:c509c83f285d4cb4aa1d2601709d1b422021-12-02T12:40:23ZIgA Nephropathy Secondary to Ipilimumab Use2296-970510.1159/000519169https://doaj.org/article/c509c83f285d4cb4aa1d2601709d1b422021-11-01T00:00:00Zhttps://www.karger.com/Article/FullText/519169https://doaj.org/toc/2296-9705Ipilimumab is a human monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 approved for the treatment of non-small-cell lung cancer (NSCLC) and other malignancies. Despite a high prevalence of other immune-related adverse events (irAEs), checkpoint inhibitor (CPI)-related nephrotoxicity has been reported less frequently. In this clinical case report, we describe the evaluation of a 70-year-old female with stage IV NSCLC who presented with nephrotic range proteinuria 4 weeks after receiving her first cycle of ipilimumab. She underwent a renal biopsy and was found to have IgA nephropathy that was presumed to be secondary to ipilimumab use, given recent initiation of therapy and clinical history. Unfortunately, despite prompt initiation of corticosteroids, her acute kidney injury progressed and she required hemodialysis, later transitioning to hospice. To our knowledge, this is one of few reported cases of IgA nephropathy secondary to CPI use. With increasing use of CPIs, this case further emphasizes the need for continued surveillance for irAEs, which can occur at any point in a patient’s treatment course.Sean C. DoughertyNisa DesaiHelen P. CathroAmanda RenaghanKarger Publishersarticleacute renal failurehistopathologyiga nephropathykidney biopsyproteinuriaDiseases of the genitourinary system. UrologyRC870-923ENCase Reports in Nephrology and Dialysis, Vol 11, Iss 3, Pp 327-333 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	acute renal failure histopathology iga nephropathy kidney biopsy proteinuria Diseases of the genitourinary system. Urology RC870-923
spellingShingle	acute renal failure histopathology iga nephropathy kidney biopsy proteinuria Diseases of the genitourinary system. Urology RC870-923 Sean C. Dougherty Nisa Desai Helen P. Cathro Amanda Renaghan IgA Nephropathy Secondary to Ipilimumab Use
description	Ipilimumab is a human monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 approved for the treatment of non-small-cell lung cancer (NSCLC) and other malignancies. Despite a high prevalence of other immune-related adverse events (irAEs), checkpoint inhibitor (CPI)-related nephrotoxicity has been reported less frequently. In this clinical case report, we describe the evaluation of a 70-year-old female with stage IV NSCLC who presented with nephrotic range proteinuria 4 weeks after receiving her first cycle of ipilimumab. She underwent a renal biopsy and was found to have IgA nephropathy that was presumed to be secondary to ipilimumab use, given recent initiation of therapy and clinical history. Unfortunately, despite prompt initiation of corticosteroids, her acute kidney injury progressed and she required hemodialysis, later transitioning to hospice. To our knowledge, this is one of few reported cases of IgA nephropathy secondary to CPI use. With increasing use of CPIs, this case further emphasizes the need for continued surveillance for irAEs, which can occur at any point in a patient’s treatment course.
format	article
author	Sean C. Dougherty Nisa Desai Helen P. Cathro Amanda Renaghan
author_facet	Sean C. Dougherty Nisa Desai Helen P. Cathro Amanda Renaghan
author_sort	Sean C. Dougherty
title	IgA Nephropathy Secondary to Ipilimumab Use
title_short	IgA Nephropathy Secondary to Ipilimumab Use
title_full	IgA Nephropathy Secondary to Ipilimumab Use
title_fullStr	IgA Nephropathy Secondary to Ipilimumab Use
title_full_unstemmed	IgA Nephropathy Secondary to Ipilimumab Use
title_sort	iga nephropathy secondary to ipilimumab use
publisher	Karger Publishers
publishDate	2021
url	https://doaj.org/article/c509c83f285d4cb4aa1d2601709d1b42
work_keys_str_mv	AT seancdougherty iganephropathysecondarytoipilimumabuse AT nisadesai iganephropathysecondarytoipilimumabuse AT helenpcathro iganephropathysecondarytoipilimumabuse AT amandarenaghan iganephropathysecondarytoipilimumabuse
_version_	1718393766116589568

IgA Nephropathy Secondary to Ipilimumab Use

Ejemplares similares